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AbsTrACT
background human neural stem cell implantation may 
offer improved recovery from stroke. We investigated the 
feasibility of intracerebral implantation of the allogeneic 
human neural stem cell line cTX0e03 in the subacute—
chronic recovery phase of stroke and potential measures 
of therapeutic response in a multicentre study.
Methods We undertook a prospective, multicentre, 
single- arm, open- label study in adults aged >40 years 
with significant upper limb motor deficits 2–13 months 
after ischaemic stroke. 20 million cells were implanted 
by stereotaxic injection to the putamen ipsilateral to the 
cerebral infarct. The primary outcome was improvement 
by 2 or more points on the action research arm Test 
(araT) subtest 2 at 3 months after implantation.
Findings Twenty- three patients underwent cell 
implantation at eight UK hospitals a median of 7 
months after stroke. One of 23 participants improved 
by the prespecified araT subtest level at 3 months, and 
three participants at 6 and 12 months. improvement in 
araT was seen only in those with residual upper limb 
movement at baseline. Transient procedural adverse 
effects were seen, but no cell- related adverse events 
occurred up to 12 months of follow- up. Two deaths were 
unrelated to trial procedures.
Interpretation administration of human neural 
stem cells by intracerebral implantation is feasible in a 
multicentre study. improvements in upper limb function 
occurred at 3, 6 and 12 months, but not in those with 
absent upper limb movement at baseline, suggesting a 
possible target population for future controlled trials.
Funding reneuron, innovate UK (application no 
32074-222145).
Trial registration number eudracT number: 2012-
003482-18
bACkground
Stroke is the second most common cause of death 
and the primary cause of long- term adult disability.1 
Cell therapies may modify early brain injury, or may 
enhance subsequent recovery from stroke through 
mechanisms that include modulation of inflamma-
tion, neural plasticity and neovascularisation via 
secretion of cytokines, growth and other factors 
in response to injury.2 Prior clinical studies have 
explored safety and feasibility of stem cell admin-
istration in either early subacute or chronic stages. 
Intravenous or intra- arterial administration of bone 
marrow or peripheral blood- derived cells of various 
kinds have been delivered predominantly in the 
subacute phase days to weeks after stroke, intended 
to modulate early secondary brain injury through 
systemic action. This has been explored in several 
small feasibility studies3–8 and in two completed 
randomised trials of insufficient size to reliably 
determine efficacy.9 10 In chronic stroke, intracere-
bral delivery of allogeneic cells of various types has 
been explored.11–13
The human neural stem cell line CTX0E03 modi-
fies the local inflammatory response, and in animal 
models promotes both host cell neurogenesis after 
stroke, and host cell angiogenesis after limb isch-
aemia.14 15 CTX0E03 cells injected 4 weeks after 
middle cerebral artery occlusion in rats showed a 
dose- dependent11 and implantation site-16depen-
dent improvement in behavioural outcome along 
with histological evidence of increased host stri-
atal angiogenesis13 and neurogenesis.14 Preclinical 
observations suggest that implanted CTX0E03 cells 
enhance tissue repair in vivo.14 15 17
In a phase I safety trial, 11 patients with stable, 
moderate to severe functional neurological impair-
ments after ischaemic stroke underwent intracere-
bral implantation of CTX0E03 cells an average of 
30 months after stroke in doses of up to 20 million 
cells.11 No cell- related safety issues were observed 
up to 24 months postimplantation, and modest 
neurological and functional improvements were 
observed in some patients. Continuing follow- up 
has identified no cell- related safety issues up to 8 
years postimplantation.
We undertook the current study of CTX0E03 cell 
implantation to explore effects on arm motor func-
tion during earlier stages of stroke recovery, gain 
further safety data and assess practicality of multi-
centre recruitment.
MeThods
We undertook an open- label, single- arm, multi-
centre study to investigate the motor response of 
the weak arm following stereotaxic intrastriatal 
injection of 20 million CTX0E03 cells ipsilateral to 
a supratentorial ischaemic stroke that had occurred 
between 2 and 13 months earlier. The study was 
overseen by an independent data and safety moni-
toring board.
copyright.
 o
n
 M
arch 27, 2020 by guest. Protected by
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322515 on 10 February 2020. Downloaded from 
397Muir KW, et al. J Neurol Neurosurg Psychiatry 2020;91:396–401. doi:10.1136/jnnp-2019-322515
Cerebrovascular disease
Patient eligibility
Full inclusion and exclusion criteria are detailed in the online 
supplementary material. We included male or non- pregnant 
female patients aged ≥40 years, with imaging- confirmed supra-
tentorial ischaemic stroke, and with stable arm weakness satis-
fying both of the following criteria at time of consent: National 
Institutes of Health Stroke Scale (NIHSS) Motor Arm score of 
2, 3 or 4; and a score of 0 or 1 for test 2 of the Action Research 
Arm Test (ARAT: grasp a 2.5 cm3 block and move it from the 
starting position to the target end position).
Main exclusion criteria were prior disabling stroke; history 
of intracranial haemorrhage; other significant functional impair-
ment of the affected arm; contraindications to MRI; life expec-
tancy <12 months; malignancy (except for non- melanoma skin 
cancer) within the previous 5 years; malignant brain tumours or 
metastases; current tamoxifen treatment; intermittent oral anti-
spasticity medication.
sample size
A minimum sample size of 21 treated patients was estimated to 
ensure that a response rate of ≥20% could not be excluded at 
the lower one- sided 50% CI for the population mean using the 
Clopper- Pearson method. The desired minimum response rate 
was 20% (5/21 subjects) achieving improvement of ≥2 points 
on ARAT test item 2, for which the probability of spontaneous 
improvement was predicted to be <5%.
outcome measures
The primary outcome was the response (improvement by ≥2 
points 3 months after cell implantation) on ARAT item 2. 
Secondary efficacy outcomes were numbers of participants 
showing a predefined minimum response on total ARAT score 
(≥6 points); NIHSS score (≥10 points); Barthel Index (≥9 
points); Fugl- Meyer motor score (≥10 points) on either Motor 
Function Upper Extremity score or Motor Function Lower 
Extremity score (added in protocol amendment 8) and modified 
Rankin Scale (mRS, ≥1 grade).
Data were analysed for the overall dataset. Post hoc subgroup 
analysis was undertaken for primary and secondary efficacy 
measures in patients grouped by baseline upper limb function 
defined by NIHSS arm motor score (4 vs 3 or 2).
The study schedule is detailed in online supplementary table 
1. Pretreatment assessments occurred from day 28 (±7 days) 
following the stroke up to 1–14 days prior to implantation of 
CTX0E03 DP (day 0). Functional outcomes were evaluated 30, 
90, 180 and 360 days after treatment.
Antiplatelet or anticoagulant treatment was withheld for 
a maximum of 7 days prior to surgery but stroke treatments 
as determined by the treating clinician otherwise continued 
throughout. All patients received a minimum 1.5 hours/week 
physiotherapy directed at the weak arm for 6 weeks. Additional 
physical and other therapy inputs were delivered according to 
individual patient needs, determined by the local clinical team.
CTX cells
CTX0E0318 is clonally derived from human fetal cortical 
neuroepithelial cells and incorporates a retrovirally inserted 
c- mycERTAM transgene that confers phenotypic and genotypic 
stability. CTX0E03 drug product (CTX0E03 DP) is a sterile 
suspension composed of CTX0E03 cells at a passage of ≤37 and 
formulated in HypoThermosol at a concentration of 5×104 cells/
μL. Growth factors and 4- hydroxytamoxifen (4- OHT) used in 
the manufacturing process are not part of the final formulation. 
Myc- dependent cell replication is curtailed by removing 4- OHT 
in cultures, restoring the cells’ capability to differentiate.19 Cryo-
preserved CTX0E03 DP has a shelf life of 6 months at −135°C 
and was thawed rapidly at the time of use.
Procedures
Under general anaesthesia, a neurosurgeon experienced in stereo-
taxic surgery injected a single intracerebral dose of 20 million 
CTX cells (400 μL CTX0E03 DP) into the putamen ipsilateral 
to the ischaemic stroke using coordinates and trajectories based 
on individual preoperative imaging, as previously described.11 20 
CTX cells were delivered in 20 μL deposits at a rate of 5 μL /min, 
pausing for at least 20 s between each bolus. The deepest implant 
was delivered first and the cannula withdrawn for subsequent 
boluses along any single trajectory. Five deposits of 20 μL each 
were placed along each of four needle tracts. Administration of 
the entire dose was completed within 3 hours of CTX0E03 DP 
being brought to room temperature.
Protocol evolution
The protocol and amendment history are included as online 
supplementary material. The initial eligibility criteria required 
an NIHSS arm score of 2 or 3: this was later amended to include 
NIHSS arm score of 4 (no movement). The primary endpoint 
was modified to day 90 from day 180 (amendment 8). Eligibility 
criteria were modified during the course of the study to remove 
an upper age limit. The Fugl- Meyer Assessment was added to 
the protocol and was therefore not conducted in all trial partici-
pants. A statistical analysis plan was finalised and approved prior 
to database lock.
Role of the funding source
ReNeuron funded the study and designed the protocol with 
input from investigators. An independent contract research 
organisation managed data collection. Analysis was undertaken 
by an independent statistician contracted to provide the study 
report. The funder was not aware of outcomes until database 
lock. The corresponding author had full access to all study data 
and had final responsibility for submission for publication.
resulTs
Patients were enrolled and treated between July 2014 and August 
2016, and follow- up completed in August 2017. Of 41 patients 
who underwent screening for eligibility, 23 proceeded to cell 
injection (figure 1). One patient died before 12- month follow- up 
(sepsis of unknown cause on day 241), and two others did not 
attend for 12- month review. Demographics, medical history and 
baseline stroke characteristics are described in table 1. Baseline 
ARAT item 2 scores were 0 in 22/23 and 1 in one participant. 
Successful implantation of CTX0E03 DP was completed in all 
23 patients.
Numbers of participants exhibiting predefined response 
criteria are detailed in table 2. Individual patient data are detailed 
in online supplementary material.
Primary endpoint
At 3 months, one patient showed ≥2 points improvement on 
ARAT item 2. Three patients exhibited a response at 6 and at 12 
months: one patient exhibiting a response at 6 months did not 
achieve the response at 12 months, but had increased scores for 
other ARAT test items (5 cm3 and 7.5 cm3 blocks).
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Figure 1 Patient disposition through the study. hla, human leucocyte 
antigen. cTX0e03 DP; cTX0e03 Drug Product.
Table 1 Demographics, medical history and stroke characteristics of 
participants
Age (years) Mean (sd), range 62.4 (10.8), 41–79
Sex
  Male:female n (%) 13 (57): 10 (43)
Race
  White/Caucasian n (%) 22 (96)
  Asian n (%) 1 (4)
Medical history
  Hypertension n (%) 12 (52)
  Atrial fibrillation n (%) 5 (22)
  Previous stroke n (%) 5 (22)
  Ischaemic heart disease n (%) 3 (13)
  Current or previous smoker n (%) 16 (70)
  Diabetes n (%) 2 (9)
  Peripheral vascular disease n (%) 2 (9)
  Smoking status
  Never smoked n (%) 7 (30)
  Previous smoker n (%) 13 (57)
  Current smoker n (%) 3 (13)
Stroke characteristics
  Onset to enrolment months Median (IQR), 
range
7 (IQR 5), range 2–13
  Affected hemisphere n (%) Left 9 (39); Right 14 (61)
  Location of infarct
  Cortical n (%) 12 (52)
  Subcortical n (%) 12 (52)
Basal ganglia n (%) 8 (35)
Internal capsule n (%) 7 (30)
Corona radiata n (%) 5 (22)
Other n (%) 2 (9)
  Both cortical and subcortical n (%) 7 (30)
  OCSP classification
  TACS n (%) 10 (43.48)
  PACS n (%) 8 (34.78)
  LACS n (%) 5 (21.74)
  NIHSS Median (range) 6 (3–15)
UL=2 n (%) 9 (39)
UL=3 n (%) 5 (22)
UL=4 n (%) 9 (39)
  Barthel Index Median (range) 70 (15–100)
  Modified Rankin Scale (mRS) Median (range) 3 (2–5)
mRS 2 n (%) 3 (13)
mRS 3 n (%) 11 (48)
mRS 4 n (%) 8 (35)
mRS 5 n (%) 1 (4)
Fugl- Meyer Assessment (n=8) Median (range)
UL 6 (2–22)
Lower limb Median (range) 18.5 (2–28)
Total Motor Score Median (range) 31.5 (4–47)
Action Research Arm Test
Total Score, affected arm Median (range) 0 (0–7)
LACS, lacunar stroke syndrome; mRS, modified Rankin Scale; NIHSS, National 
Institutes of Health Stroke Scale; OCSP, signifies Oxfordshire Community Stroke 
Project; PACS, partial anterior circulation stroke; TACS, total anterior circulation 
stroke; UL, upper limb.
secondary endpoints
Total ARAT score improved at the last observation in 7/23 
patients, with individual improvements ranging between 1 and 
54 points. Five (22%) patients met the response criterion of 
improvement by ≥6 points. No participant exhibited a change 
in total NIHSS score of 10 or more points as defined in the 
statistical analysis plan therefore this is omitted from table 2; 
however, only four participants had baseline NIHSS >10. 
Change in Barthel Index of ≥9 points was seen in 8/20 partici-
pants at 12 months, but could not be evaluated in six subjects in 
whom baseline score was 95 or 100 (ceiling). Fugl- Meyer motor 
scores were undertaken in only 10 participants and improved by 
≥10 points in 3. Improvement in mRS by ≥1 grade was seen in 
7/20 participants at 12 months (details in table 2).
secondary analyses
Responses rates in prespecified assessments were explored with 
respect to age, time elapsed since stroke and baseline NIHSS arm 
motor scores. No participant exhibited a response to all four 
scales at any time point; the number of participants exhibiting 
a response to 3, 2 or 1 scales was 1, 4 and 8 at 3 months, 2, 3 
and 8 at 6 months, and 3, 3 and 8 at 12 months (online supple-
mentary figure 1). Changes in mRS grade were from grade 5 to 
3 in one patient; from grade 4 to grade 3 in two patients, both of 
whom returned to grade 4 at subsequent visits, and one of whom 
died before the 12 months assessment; grade 3 to grade 2 in five 
patients and grade 2 to grade 1 in one patient.
At 6 months, 4/22 participants exhibited improvement in either 
ARAT subitem 2 or total ARAT: the responders were signifi-
cantly younger (mean 53±6 years vs 64±11 years, p=0.025) but 
had no differences in time elapsed from stroke to intervention 
or total baseline NIHSS compared with non- responders. At 12 
months, 5/20 participants exhibited ARAT response as above, 
but no differences were seen in age, baseline NIHSS or time to 
intervention compared with non- responders.
In nine participants, baseline NIHSS arm motor score was 
4 (no movement); 14 participants had scores of 2 or 3, signi-
fying at least some movement. Compared with patients with 
NIHSS arm scores of 2 or 3, patients with no upper limb move-
ment (NIHSS 4) at baseline were significantly older (70±8 vs 
57±9 years, p=0.002), had higher total NIHSS scores (median 
7.5 (IQR 7) vs 6 (IQR 4), p=0.019) and lower Barthel scores 
(median 55 (IQR 38) vs 90 (IQR 31), p=0.003), but interval 
from stroke onset to treatment did not differ (median 8.5 (IQR 
5) months vs 7 (IQR 6)). Responses on ARAT item 2 or total 
score were seen in none of those with baseline NIHSS arm score 
of 4 (figure 2 and online supplementary table 2). Improvement 
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Table 2 Responders to primary and secondary endpoints
response definition
ArAT subtest 2 
(grasp) primary 
outcome ArAT total response
modified rankin 
scale barthel Index FMA one or more of 
ArAT, mrs or bI, 
(%)
≥2 point 
improvement, (%)
>6 point 
improvement, (%)
>1 category 
improvement, (%)
>9 point 
improvement*, (%)
>10 point 
improvement†, (%)
3 months 1/23 (4) 3/23 (13) 7/23 (30) 8/23 (35) 4/10 (40) 13/23 (57)
6 months 3/22 (14) 4/22 (18) 6/22 (27) 7/22 (32)   13/22 (59)
12 months 3/20 (15) 5/20 (25) 7/20 (35) 8/20 (40) 3/10 (30) 14/20 (70)
*Improvement by the specified threshold could not be evaluated in three subjects in whom baseline score was 100 and three subjects in whom baseline score was 95.
†Response on Fugl- Meyer Assessment is ≥10 points on either Motor Function Upper Extremity score or Motor Function Lower Extremity score.
ARAT, signifies Action Research Arm Test; BI, Barthel Index; FMA, Fugl- Meyer Assessment; mRS, modified Rankin Scale.
Figure 2 Median total araT score subdivided by baseline nihss upper 
limb motor score. solid horizontal lines represent median, boxes iQr, error 
bars maximum and minimum values. araT, action research arm Test; 
nihss, national institutes of health stroke scale.
Table 3 Serious adverse events (SAEs) occurring after surgery during 
the study period
system (n subjects) event n events
Timing of sAe 
start (days 
postprocedure)
Infections (n=5) Sepsis 2 22, 241
Gastroenteritis 1 108
Lower respiratory tract 
infection
1 2
Urinary tract infection 1 118
Viral infection 1 234
Central nervous system 
(n=5)
Headache 2 214, 1
Carotid stenosis 1 0
Hypertonia 1 1
Ischaemic Stroke 1 1
Partial seizure 1 22
Gastrointestinal (n=1) Vomiting 1 2
Procedural (n=1) Subdural haemorrhage 1 25
Immunological (n=1) HLA positivity 1 33
Psychiatric (n=1) Suicide 1 342
Respiratory (n=1) Aspiration pneumonia 1 120
HLA, signifies human leucocyte antigen.
by one or more grades of the mRS at month 12 was seen in 6/12 
(50%) patients with baseline NIHSS 2 or 3, and in 1/8 (12.5%) 
of those with baseline NIHSS arm score of 4. Individual patient 
data for all endpoints are detailed in online supplementary table 
3. Responses were seen in both those with cortical and isolated 
subcortical infarcts (online supplementary table 4).
safety
There were 17 serious adverse events (SAEs) in 11 patients 
(table 3). These included two deaths (sepsis on day 241, and 
completed suicide 7 days after the final study visit) consid-
ered unrelated to study procedures. Six SAEs in four patients 
were considered related to the surgical procedure, all of which 
resolved. These were: cerebral infarction identified on day 1 
postprocedure, in a patient with carotid artery stenosis who had 
required prolonged general anaesthesia; subdural haemorrhage 
identified on day 2 postprocedure; headache and vomiting (days 
2–4 postprocedure); and partial seizures and sepsis in one partic-
ipant (day 22 postprocedure) considered by local investigators 
to be possibly related to CTX0E03 cells. The seizure episode 
was a single, 1- hour long episode of shaking, commencing 
focally in one upper limb then spreading to the opposite arm 
and whole body. The patient was conscious throughout. Onset 
was concurrent with sepsis. Cerebrospinal fluid screen and 
culture were both negative, and no source of infection could be 
confirmed.
One patient experienced the serious event of transient, weakly 
detectable human leucocyte antigen antibody, to antigens which 
are not expressed by the CTX0E03 cell line, coincident with 
an intercurrent chest infection 33 days postprocedure. Infection 
was considered to be the likely stimulus for a non- specific immu-
nological reaction.
Three patients experienced hypotension during the surgery, 
and two of these also experienced bradycardia, one during the 
surgery and one during the postoperative inpatient period.
dIsCussIon
This second study of intracerebral CTX0E03 human neural 
stem cell injection extends the initial clinical data in several 
important respects. First, the feasibility of a multicentre clinical 
study was confirmed. The development of frozen cell product 
was an important technical development since the first Pilot 
Investigation of Stem Cells in Stroke (PISCES-1) trial to enable 
this. Second, additional safety data at the 20 million cell dose 
confirm few potentially cell- related adverse events up to 1 year 
of follow- up in both male and female participants, and in a 
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wider age range than previously studied. Third, the feasibility 
of recruitment at earlier time points following stroke has been 
established. In the previous PISCES-1 study, median time from 
stroke to cell implantation was 30 months, compared with 7.5 
months in the present study. Finally, exploratory data on func-
tional outcome measures indicate both that the responder rate 
in a population expected to have a low incidence of function-
ally useful clinical improvement was sufficient to justify further 
clinical investigation, and that response rates on measures of 
upper limb function are likely to be poor among patients with 
completely absent upper limb movement at baseline assessment 
a median of 7.5 months after stroke. Preliminary data exploring 
activities of daily living, general disability and motor function 
suggest a range of suitable clinical outcome measures for future 
research.
The original study design sought to determine whether a suffi-
cient proportion of patients experienced response of their weak 
arm 3 months after implantation of CTX0E03 DP to justify 
further investigation. The intent was to exclude response rates 
below 20% with 90% CI at this 3 month time point. At the 
3- month evaluation, only one patient met criteria for ARAT test 
2 response, and so the primary efficacy endpoint was not met. 
However, additional patients responded at 6 and 12 months 
suggesting that improvement continues beyond the 3- month time 
point. Overall, three participants (15% of those who completed 
12- month follow- up) achieved an increase of at least 2 points at 
12 months, and one further patient responded at 6 months but 
not at 12 months, although increased scores for the larger sized 
blocks assessed in the ARAT. Given the arbitrary selection of 3 
months as a time point for endpoint evaluation, and absence of 
safety issues, further evaluation of CTX0E03 DP in randomised 
clinical trials is justified.
Most stroke patients experience some functional recovery in 
the first 6 months poststroke,21–23 varying with severity of the 
initial deficit.24 Patients who improve early have more favour-
able functional outcome regardless of clinical syndrome, while 
patients who fail to show significant recovery by day 10 retain 
significant disability at day 90.25 Prediction models adjusted 
for the effects of time after stroke onset suggest that outcome 
is largely defined within the first weeks poststroke.26 Clinical 
predictors of dexterity at 6 months are severity of initial arm 
weakness, and arm motor recovery in the first month after 
stroke, with no further improvement in prediction accuracy 
beyond this time.26–29 PISCES-2 participants were selected on 
the basis of poor predicted recovery, yet showed functionally 
relevant improvement in motor functions. Observations from 
the current study as well as the previous PISCES-1 study indicate 
potential worthwhile functional improvements even with inter-
vention occurring in the late subacute or chronic stages after 
stroke.
The functional improvements observed in the study popula-
tion are unlikely to have arisen as a consequence of additional 
physical therapy at the dose delivered, since very much larger 
doses appear to be necessary for an effect in chronic stroke.30 31 
However, the possibility that lower doses of physical therapy 
interact with stem cell administration could not be excluded. We 
did not specifically assess other potential confounders that may 
lead to falsely low motor performance such as pain or percep-
tual deficits, therefore, cannot completely exclude the possi-
bility that other factors may have been relevant in the observed 
improvement.
Expert consensus statements on trial reporting standards,32 
measurement33 and biomarkers34 were produced after the initi-
ation of PISCES-2, but the trial conformed with many of these 
recommendations, including the use of NIHSS to characterise 
stroke severity, ARAT as a measure of upper limb function and 
the mRS as a measure of global disability. However, the trial 
framework proposed did not make recommendations regarding 
stroke recovery studies where the intervention commenced only 
in the chronic stage of stroke.
Observations in PISCES-2 inform some aspects of future trial 
design. The ARAT response observed in PISCES-2 was related 
to the baseline degree of arm motor impairment, with no ARAT 
responders among those with absence of movement (NIHSS 
motor arm score of 4) at baseline. Improvements in mRS were 
also rarely observed in participants with absent arm movement 
at study entry. The Barthel index has notable ceiling effects that 
limit its utility, and in keeping with this, six participants could 
not achieve a response since already scoring near- maximum or 
maximum scores at baseline.35 Consensus recommendations on 
appropriate outcome measures from the Stroke Recovery and 
Rehabilitation Roundtable group33 include the ARAT for upper 
limb function. Previous exploratory work on sample size require-
ments for motor recovery trials36 assuming a defined minimum 
clinically important difference (MCID) on ARAT of 6 points 
was based on a small sample size and early characterisation of 
patients: it is unclear whether the assumed MCID or changes 
over time apply in later subacute or chronic stages after stroke. 
Additional work to characterise predictors of motor response 
at later time points poststroke would be beneficial in stratifying 
patients for future trials, particularly where an invasive therapy 
is involved. Motor response prediction algorithms developed for 
early poststroke use, which include clinical evaluation supple-
mented where necessary by transcranial magnetic stimulation to 
determine the integrity of corticospinal tracts supplying upper 
limb muscles,37 may not be applicable to later time points and 
require validation.34 For confirmation of clinically important 
functional outcome changes in stroke, the modified Rankin Scale 
has been favoured by regulatory bodies, and our observations 
support this approach.
There are a number of limitations to this study. The open- 
label design was adopted due to the early stage of clinical inves-
tigation but may bias functional assessments. Future evaluation 
in a randomised, controlled trial is essential. Small numbers of 
participants inevitably mean that the heterogeneity of stroke 
cannot be adequately represented, and means that any interpre-
tation of factors related to functional or neurological response 
must be extremely cautious. Factors, such as age, medical comor-
bidities, infarct volume and location, anatomical and functional 
involvement of the corticospinal tract, time elapsed since the 
stroke, the anatomical location and distribution of cell deposits, 
concomitant physical therapy and its intensity, may all contribute 
significantly to motor and general recovery, and a much larger 
study would be required to evaluate these. While we observed 
a low incidence of potentially cell- related adverse events, the 
total number of patients implanted is small (23 in the current 
study and 2 at this dose level in PISCES-1) and follow- up period 
limited.
In conclusion, PISCES-2 provides additional data to support 
multicentre clinical trials of intracerebral stem cell injection 
in subacute stages of stroke recovery. Functionally relevant 
improvement in arm movement was observed in patients with 
residual upper limb motor function at baseline. Further clin-
ical investigation in a randomised, controlled clinical trial is 
warranted.
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